Amgen Stocks Rise 5.91% as Higher Guidance Narrows the Remaining Earnings Test

What happened

Amgen raised its full-year revenue outlook to $38.9 billion–$39.7 billion, from $38.2 billion–$39.4 billion, and its non-GAAP earnings forecast to $22.90–$23.70 per share. Third-quarter revenue rose 8% to $10.4 billion, while non-GAAP earnings per share increased 14% to $6.45.

Confirmed

Global impact / market context

The higher forecast gives Amgen a stronger expected earnings base, but the revenue midpoint rose only about 1.3%. Investors’ return case therefore depends on whether product sales keep expanding enough to support profits while the company funds development of future medicines.

Analyst inference

The quarter’s earnings growth outpaced revenue growth, suggesting profits rose faster than sales during the period. That may strengthen the operating picture, but the article also flags financial strength as a weaker score area, making the ability to fund future medicines without weakening its finances relevant.

Analyst inference

What to watch

1. Compare upcoming revenue and non-GAAP earnings with the revised annual ranges to see whether the stronger forecast is supported by continued business results. Analyst inference
2. Look for further management guidance on product demand and spending on future medicines; the article identifies both as tests for sustaining sales growth and profits. Analyst inference
3. Watch whether earnings continue growing faster than revenue, while tracking financial strength, which the cited scorecard rates as weaker than profitability and growth. Analyst inference

Evidence

• gurufocus.com